Israeli generic drugmaker Teva Pharmaceutical Industries Ltd. will buy its U.S. rival Barr Pharmaceuticals Inc. for $8.9 billion, in cash, stock and the assumption of debt, it said Friday. Teva already holds the mantle of largest generic drugmaker in the world, and the move to acquire Barr increases its reach further with access to the rapidly expanding Central and Eastern European markets. Teva relied on Willkie Farr & Gallagher and Israeli firm Tulchinsky Stern Marciano Ben-Zur Cohen & Co. for legal help.
July 18, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Israeli generic drugmaker Teva Pharmaceutical Industries Ltd. will buy its U.S. rival Barr Pharmaceuticals Inc. for $8.9 billion, in cash, stock and the assumption of debt, it said Friday.
Barr shareholders will receive $39.90 in cash and 0.6272 of an American depositary receipt of Teva, valuing each Barr share at $66.50.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
